What is claimed is:

A pharmaceutical composition comprising: (a) a tumor necrosis factor inhibitor; (b) a compound selected from the group consisting of reverse transcriptase inhibitors, protease inhibitor, a gene inhibitor, myristoylation inhibitors, cell-virus binding inhibitors, LTR promoter site inhibitors, ribosome inactivators, platelet aggregation inhibitors and prophylactic and therapeutic HIV vaccines, and (c) a pharmaceutical inert nontoxic carrier.

The composition of claim 1 wherein said tumor necrosis factor inhibitor is selected from the group consisting of thalidomide, pentoxifylline and xanthine derivatives.

3. The composition of claim 1 wherein said reverse transcriptase inhibitor is selected from the group consisting of AZT, ddl and ddc.

The composition of claim 2 wherein said tumor necrosis factor inhibitor is thalidomide.

- The composition of claim 3 wherein said reverse transcriptase inhibitor is AZT.
- 6. The composition of claim 1 wherein said tumor/necrosis factor inhibitor is thalidomide and said reverse transcriptase inhibitor is AZT.
- The composition of claim 1 wherein said tumor necrosis factor inhibitor is pentoxifylline and said reverse transcriptase inhibitor is AZT.

- 8. The composition of claim 1 wherein said TNF inhibitor is thalidomide and said reverse transcriptase inhibitor is ddl.
- 9. The composition of claim 1 wherein said TNF inhibitor is pentoxifylline and said reverse transcriptase inhibitor is ddl.
- 10. The composition of claim 2 wherein said TNF inhibitor is thalidomide and said reverse transcriptase inhibitor is ddc.
- 11. The composition of claim 1 wherein said TNF inhibitor is pentoxifylline and said reverse transcriptase inhibitor is odc.
- 12. The composition of elaim 1 wherein said TNF inhibitor is thalidomide and said gene inhibitor is the tat-inhibitor RO-24-7429.
- 13. The composition of claim 1 wherein said NF inhibitor is thalidomide and said myristoylation inhibitor is AC₂.
- 14. The composition of claim 1 wherein said TNF inhibitor is thalidomide and said reverse transcriptase inhibitor is lipophilic prodrug/of AZT.
- 15. The composition of claim 1 wherein said TNF inhibitor is thalidomide and said reverse transcriptase inhibitor is FddT.

- 16. The composition of claim 1 wherein said TNF inhibitor is thalidomide and said reverse transcriptase inhibitor is D4T.
- 17. The composition of claim 1 wherein said TNF inhibitor is thalidomide and said reverse transcriptase inhibitor is 3TC.
- 18. The composition of claim 1 wherein said TNF inhibitor is thalidomide and said reverse transcriptase inhibitor is BI-RG-587.
- 19. The composition of claim 1 wherein said TNF inhibitor is thalidomide and said reverse transcriptase inhibitor is R-82150.
- 20. The composition of claim 1 wherein said TNF inhibitor isthalidomide and said reverse transcriptase inhibitor is L697639.

ad. 7